The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

Manno, 2006, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat. Med., 12, 342, 10.1038/nm1358 Andrzejewski, 2019, Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus, Gene Ther., 26, 250, 10.1038/s41434-019-0076-5 Liu, 2014, Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors, Gene Ther., 21, 732, 10.1038/gt.2014.47 Daniel, 2021, Prevalence of adeno-associated virus 3 capsid binding and neutralizing antibodies in healthy and hemophilia B individuals from India, Hum. Gene Ther., 32, 451, 10.1089/hum.2020.258 Lee, 2019, Relationship between neutralizing antibodies against adeno-associated virus in the vitreous and serum: effects on retinal gene therapy, Transl. Vis. Sci. Technol., 8, 14, 10.1167/tvst.8.2.14 Kruzik, 2019, Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors, Mol. Ther. Methods Clin. Dev., 14, 126, 10.1016/j.omtm.2019.05.014 Khatri, 2022, Higher seroprevalence of anti-adeno-associated viral vector neutralizing antibodies among racial minorities in the United States, Hum. Gene Ther., 33, 442, 10.1089/hum.2021.243 Mimuro, 2014, The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals: prevalence of Antibodies against AAV, J. Med. Virol., 86, 1990, 10.1002/jmv.23818 Klamroth, 2022, Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A, Hum. Gene Ther., 33, 432, 10.1089/hum.2021.287 Greenberg, 2016, Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure, Gene Ther., 23, 313, 10.1038/gt.2015.109 Calcedo, 2009, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses, J. Infect. Dis., 199, 381, 10.1086/595830 Boutin, 2010, Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors, Hum. Gene Ther., 21, 704, 10.1089/hum.2009.182 Li, 2012, The Joint Outcome Study Investigators (2012). Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther., 19, 288, 10.1038/gt.2011.90 Dunbar, 2018, Gene therapy comes of age, Science, 359, 10.1126/science.aan4672 Reiss, 2021, Hemophilia gene therapy—new country initiatives, Haemophilia, 27, 132, 10.1111/hae.14080 2021, Project entrusted by Ministry of Health, Labor and Welfare, Nationwide Surv. Coagul. Disord., 2021 Aronson, 2019, Prevalence and relevance of pre-existing anti-adeno-associated virus immunity in the context of gene therapy for crigler–najjar syndrome, Hum. Gene Ther., 30, 1297, 10.1089/hum.2019.143 Leborgne, 2019, Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients, Cell. Immunol., 342, 10.1016/j.cellimm.2018.03.004 Kiyohara, 2007, Shifting seroepidemiology of hepatitis A in Japan, Microbiol. Immunol., 51, 185, 10.1111/j.1348-0421.2007.tb03900.x Chen, 2005, Molecular characterization of adeno-associated viruses infecting children, J. Virol., 79, 14781, 10.1128/JVI.79.23.14781-14792.2005 Lion, 2019, Adenovirus persistence, reactivation, and clinical management, FEBS Lett., 593, 3571, 10.1002/1873-3468.13576 Perocheau, 2019, Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort, Hum. Gene Ther., 30, 79, 10.1089/hum.2018.098 Calcedo, 2016, AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees, Hum. Gene Ther. Clin. Dev., 27, 79, 10.1089/humc.2016.048 Hamilton, 2004, Adeno-associated virus site-specific integration and AAVS1 disruption, J. Virol., 78, 7874, 10.1128/JVI.78.15.7874-7882.2004 Hernandez, 1999, Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model, J. Virol., 73, 8549, 10.1128/JVI.73.10.8549-8558.1999 Edara, 2021, Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination, JAMA, 325, 1896, 10.1001/jama.2021.4388 Stanford, 2019, Adenovirus-associated antibodies in UK cohort of hemophilia patients: a seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A, Res. Pract. Thromb. Haemost., 3, 261, 10.1002/rth2.12177 2015, Project entrusted by Ministry of Health, Labor and Welfare, Nationwide Surv. Coagul. Disord. 2015 Mauser-Bunschoten, 1998, High prevalence of parvovirus B19 lgG antibodies among Dutch hemophilia patients, Vox Sang., 74, 225, 10.1046/j.1423-0410.1998.7440225.x Nathwani, 2014, Long-term safety and efficacy of factor IX gene therapy in hemophilia B, N. Engl. J. Med., 371, 1994, 10.1056/NEJMoa1407309 Majowicz, 2017, Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5 ch and AAV1, Mol. Ther., 25, 1831, 10.1016/j.ymthe.2017.05.003 Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys. 10. Monteilhet, 2011, A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8, Mol. Ther., 19, 2084, 10.1038/mt.2011.108 Mimuro, 2013, Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors, Mol. Ther., 21, 318, 10.1038/mt.2012.258 Meliani, 2018, Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration, Nat. Commun., 9, 4098, 10.1038/s41467-018-06621-3 Batty, 2022, Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A, Blood, 10.1182/blood.2021014735 George, 2020, Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B, Mol. Ther., 28, 2073, 10.1016/j.ymthe.2020.06.001 Halbert, 2006, Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors, Hum. Gene Ther., 17, 440, 10.1089/hum.2006.17.440 Majowicz, 2019, Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs, Mol. Ther. Methods Clin. Dev., 14, 27, 10.1016/j.omtm.2019.05.009 2017, Project entrusted by Ministry of Health, Labor and Welfare, Nationwide Surv. Coagul. Disord. 2017 Grieger, 2006, Production and characterization of adeno-associated viral vectors, Nat. Protoc., 1, 1412, 10.1038/nprot.2006.207 Baatartsogt, 2021, A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid, Mol. Ther. Methods Clin. Dev., 22, 162, 10.1016/j.omtm.2021.06.004